A panel of experts provide an overview of the disease burden associated with leukemia and lymphoma, discuss the current treatment landscape of BTK inhibitors, and offer payer considerations in treatment management.
EP. 2: Prevalence, Diagnosis, and Management of CLL, MCL, and SLLJanuary 25th 2023
Brian Koffman, MD, and Callie Coombs, MD, provide the prevalence and incidence rates of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL), and describe how the diagnosis and management of CLL/MCL/SLL impacts a patient’s quality of life.
EP. 4: BTKi Landscape for CLL, MCL, and SLLFebruary 1st 2023
Callie Coombs, MD, discusses recent changes you have seen in the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL) and provides an overview of the Bruton tyrosine kinase inhibitor landscape for CLL, MCL, and SLL.